Analyst Mike Kratky from Leerink Partners reiterated a Buy rating on NeuroPace (NPCE – Research Report) and keeping the price target at $18.00.
Mike Kratky has given his Buy rating due to a combination of factors that highlight NeuroPace’s strong market position and growth potential. The company has announced that it anticipates minimal impact from the newly implemented tariffs, which is reassuring for investors concerned about tariff-related volatility. This stability allows the focus to remain on the company’s core strengths and growth strategies.
NeuroPace is experiencing strong trends in the adoption of its RNS system and is seeing increasing contributions from Project CARE. Additionally, there is potential for the company to expand its indications into generalized epilepsy later this year, which could further enhance its market position. These factors, along with the company’s reiterated gross margin guidance for FY25, suggest a promising outlook for NeuroPace, justifying the Buy rating.
In another report released yesterday, Lake Street also reiterated a Buy rating on the stock with a $20.00 price target.
NPCE’s price has also changed dramatically for the past six months – from $6.460 to $10.670, which is a 65.17% increase.